Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | FOS | P01100 | 1/20 | 0.36 |
| ▸ | TTR | P02766 | 1/20 | 0.36 |
| ▸ | JUN | P05412 | 1/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.36 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.34 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | LDHA | P00338 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20440806 | 0.80 | ADRB2 (0.38) | — | |
| SCHEMBL14992642 | 0.78 | RARB (0.32) | ALOX15 | |
| SCHEMBL20440792 | 0.78 | GAA (0.40) | HIF1AGAAMAPTPDCD1ACE2 | |
| SCHEMBL14992777 | 0.74 | POLB (0.36) | — | |
| SCHEMBL20440810 | 0.73 | DUSP3 (0.38) | — | |
| SCHEMBL14993194 | 0.71 | AR (0.37) | — | |
| SCHEMBL14993790 | 0.70 | HTR2A (0.47) | GAAMAPT | |
| SCHEMBL20440799 | 0.70 | ACE2 (0.44) | ALOX15PDCD1ACE2CD274 | |
| SCHEMBL13548297 | 0.70 | FOS (0.50) | FOSTTRJUNNR3C1HSD17B1 | |
| SCHEMBL20440802 | 0.69 | GAA (0.40) | HIF1AGAAMAPTPDCD1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10040749-B2 | Opsin-binding ligands, compositions and methods of use | BIKAM PHARMACEUTICALS INC. (US) | 2018-08-07 | — | — | US | claimed |
| US-10040749-B2 | Opsin-binding ligands, compositions and methods of use | BIKAM PHARMACEUTICALS INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-10040749-B2 | Opsin-binding ligands, compositions and methods of use | BIKAM PHARMACEUTICALS INC. (US) | 2018-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10040749-B2 | Opsin-binding ligands, compositions and methods of use | CRYAB, CRYAA, PDE6C | HIF1A 4133/4885FOS 3289/4885TTR 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.